Clinical Trials

Sponsor: Emory University

Sponsor Study ID: 4363-18

Study Title: A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

NCT Number: NCT03872180

Phase: II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Non-Hodgkin's Lymphoma

Study Objectives: This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bendamustine, obinutuzumab, and venetoclax may work better in treating patients with mantle cell lymphoma.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.